Comparative study of the effect of direct acting antivirals (DAAS) agents versus combined pegylated interferon and Ribavirin therapy on fibrosis regression in chronic HCV patients / Omnia Mohamed Mohamed Saad Tantawi ; Supervised Maissa Elsaid Elraziky , Ahmed Fouad Soliman , Ahmed Mohamed Salama
Material type: TextLanguage: English Publication details: Cairo : Omnia Mohamed Mohamed Saad Tantawi , 2016Description: 126 P. : charts ; 25cmOther title:- و علاج الانترفيرون و الريبافيرين فب مرضى التهاب الكبد الوبائى المزمن سى (DAAs) دراسة لمقارنة تناقص النسيج الليفى بين الأدوية ذات التأثير المباشر المضادة للفيروسات [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.Ph.D.2016.Om.C (Browse shelf(Opens below)) | Not for loan | 01010110070287000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.Ph.D.2016.Om.C (Browse shelf(Opens below)) | 70287.CD | Not for loan | 01020110070287000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
Hepatitis C virus (HCV) is a major public health problem in Egypt. Treatment with interferon-based therapy can lead to reversal of fibrosis. DAAs cure - 90% of patients with HCV; it is not known how treatment response will be reflected on long term clinical outcomes. Transient elastography (TE) using Fibroscan is reliable for assessment of liver fibrosis in patients with chronic HCV. Evaluation of fibrosis changes (using TE and non-invasive markers) in patients who received DAAs in comparison to those who received INF / RBV. The study was conducted on 204 patients with chronic HCV; divided into three groups according to treatment regimen. Group 1(n = 68) received peg IFN and RBV, group 2 (n = 69) received sofosbuvir and RBV and group 3 (n = 67) received peg IFN, RBV and Sofosbuvir. Patients were categorized into three stages of fibrosis; non-significant fibrosis (< F2), significant fibrosis ({u2265}F2 < F4) and cirrhosis (F4). All patients were subjected to pretreatment laboratory evaluation and assessment of fibrosis with TE, APRI and FIB-4. Follow up of all patients with TE, APRI and FIB-4 was done at least 3 months after end of treatment
Issued also as CD
There are no comments on this title.